PT  - JOURNAL ARTICLE
AU  - Colvin-Adams, Monica
AU  - Taylor, Anne L.
TI  - Interpreting the African American Heart Failure Trial(A-HEFT)
DP  - 2007 Mar 01
TA  - Cleveland Clinic Journal of Medicine
PG  - 227--234
VI  - 74
IP  - 3
4099  - http://www.ccjm.org/content/74/3/227.short
4100  - http://www.ccjm.org/content/74/3/227.full
SO  - Cleve Clin J Med2007 Mar 01; 74
AB  - The African American Heart Failure Trial (A-HeFT) found that African American patients with advanced heart failure fared better if the fixed-dose combination of isosorbide dinitrate and hydralazine was added to their regimen, which for most of them already included an angiotensin-converting enzyme (ACE) inhibitor or angiotensin-receptor blocker (ARB), a beta-blocker, and a diuretic (N Engl J Med 2004; 351:2049–2057). This placebo-controlled trial was the first to evaluate a therapy in a specific racial group, and it points the way to a more individualized approach to heart failure therapy.